Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005652 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00005652 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT00005652, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these patients.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2000-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005652
The ClinicalTrials.gov registry entry for NCT00005652 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT00005652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005652 about?
NCT00005652 is a clinical study titled "Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura". OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in t...
What is the current status of trial NCT00005652?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2000-12.
What interventions are being tested in trial NCT00005652?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT00005652?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.